Barclays Issues Pessimistic Forecast for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its price target reduced by Barclays from $255.00 to $235.00 in a research report report published on Monday morning,Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock.

Other equities research analysts also recently issued reports about the stock. Bank of America reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday. Finally, TD Cowen reduced their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $254.53.

IQVIA Price Performance

NYSE:IQV opened at $199.34 on Monday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a market cap of $36.18 billion, a price-to-earnings ratio of 26.16, a P/E/G ratio of 2.15 and a beta of 1.48. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The firm’s 50-day simple moving average is $200.41 and its 200 day simple moving average is $220.32.

Institutional Investors Weigh In On IQVIA

Hedge funds have recently added to or reduced their stakes in the business. FMR LLC grew its stake in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. JPMorgan Chase & Co. raised its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares during the last quarter. Impax Asset Management Group plc raised its holdings in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares in the last quarter. Nordea Investment Management AB boosted its position in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of IQVIA by 3.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after acquiring an additional 39,772 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.